Search Result

Results for "

region selectivity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (4) Androgen Receptor (1) Antibiotic (1) Apoptosis (8) Aurora Kinase (1) Bacterial (1) c-Met/HGFR (1) Caspase (1) Checkpoint Kinase (Chk) (1) CRM1 (1) DGK (2) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (3) EGFR (1) Endogenous Metabolite (1) Epigenetic Reader Domain (2) Fungal (1) Isotope-Labeled Compounds (1) MMP (1) Notch (1) PCSK9 (1) Ras (1) Reference Standards (1) α-synuclein (4)
By Research Areas:	Cancer (15) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (2) Neurological Disease (9)

By Targets:

Amyloid-β (4)

Androgen Receptor (1)

Antibiotic (1)

Apoptosis (8)

Aurora Kinase (1)

Bacterial (1)

c-Met/HGFR (1)

Caspase (1)

Checkpoint Kinase (Chk) (1)

CRM1 (1)

DGK (2)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (3)

EGFR (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (2)

Fungal (1)

Isotope-Labeled Compounds (1)

MMP (1)

Notch (1)

PCSK9 (1)

Ras (1)

Reference Standards (1)

α-synuclein (4)

By Research Areas:

Cancer (15)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (2)

Neurological Disease (9)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: SHP1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113294

3-Hydroxykynurenine 3-Hydroxy-DL-kynurenine	Endogenous Metabolite Apoptosis	Neurological Disease
3-Hydroxykynurenine, a metabolite of tryptophan, is a potential endogenous neurotoxin whose increased levels have been described in several neurodegenerative disorders. 3-Hydroxykynurenine induces neuronal apoptosis .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-112299

Zipalertinib 3 Publications Verification TAS6417; CLN-081	EGFR Apoptosis	Cancer
Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and *pan-mutation-selective* EGFR** tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC₅₀ values ranging from 1.1-8.0 nM .

HY-112373

Aurora kinase inhibitor-3	Aurora Kinase	Others
Aurora kinase inhibitor-3 is a strong and selective Aurora A kinase inhibitor with an IC₅₀ of 42 nM, and weakly inhibits EGFR with an IC₅₀ of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket .

HY-121638A

(5Z,2E)-CU-3 1 Publications Verification	Apoptosis DGK	Cancer
(5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of DGK with an IC₅₀ value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a K_m value of 0.48 mM. (5Z,2E)-CU-3 targets the catalytic region, but not the regulatory region of DGKα. (5Z,2E)-CU-3 has antitumoral and proimmunogenic effects, enhances the apoptosis of cancer cells and the activation of T cells .

HY-117865

GNE-886	Epigenetic Reader Domain	Cancer
GNE-886 (Compound 21) is a potent and selective inhibitor of Cat eye syndrome chromosome region candidate 2 bromodomain (CECR2) (BRD) with an IC₅₀ value of 0.016 µM and an EC₅₀ value of 370 nM. GNE-886 also inhibits BRD9 with an IC₅₀ value of 1.6 µM .

HY-P990109

Aducanumab (Mouse IGG2a)	Amyloid-β	Neurological Disease
Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC₅₀s of >1 μM and 0.2 nM for monomeric Aβ_1-40 and fibrillar Aβ_1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .

HY-120088

PF-06446846	PCSK9	Cardiovascular Disease
PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region .

HY-146384

CRM1 degrader 1	CRM1	Cancer
CRM1 degrader 1 (1l) is a low toxic chromosome region maintenance 1 (CRM1) degrader. CRM1 is the sole nuclear exporter of several tumor suppressor, a growth regulatory protein as an attractive cancer agent target. CRM1 degrader 1 induces the apoptosis in gastric carcinoma and selectively inhibits proliferation of gastric cancer .

HY-121638

CU-3	Apoptosis DGK	Inflammation/Immunology Cancer
CU-3 is the racemate of (5Z,2E)-CU-3. (5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of DGK with an IC₅₀ value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a K_m value of 0.48 mM. (5Z,2E)-CU-3 targets the catalytic region, but not the regulatory region of DGKα. (5Z,2E)-CU-3 has antitumoral and proimmunogenic effects, enhances the apoptosis of cancer cells and the activation of T cells .

HY-147259

Dalmelitinib	c-Met/HGFR	Cancer
Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC₅₀: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .

HY-164523

PV1162	Checkpoint Kinase (Chk)	Cancer
PV1162 is a selective Chk2 inhibitor with an IC₅₀ of 0.29 nM. PV1162 inhibits ATP binding to Chk2 by targeting the gatekeeper-dependent hydrophobic pocket, which is specific to Chk2 and located behind the ATP-binding site (adenine-binding region), thereby inhibiting the phosphorylation activity of Chk2. PV1162 holds potential application value in the field of cancer therapy .

HY-401209

Synucleozid-2.0	α-synuclein DNA/RNA Synthesis	Neurological Disease
Synucleozid-2.0 is a small-molecule inhibitor targeting the iron-responsive element (IRE) structure in the 5' untranslated region (5'UTR) of SNCA mRNA. Synucleozid-2.0 inhibits ribosome assembly onto SNCA mRNA and selectively reduces α-synuclein protein translation. Synucleozid-2.0 is promising for research of Parkinson's disease (PD) and related α-synucleinopathies .

HY-151523

KRas G12R inhibitor 1	Ras	Cancer
KRas G12R inhibitor 1 is a covalent inhibitor targeting the common oncogenic mutant KRas G12R with selectivity for the mutant arginine. KRas G12R inhibitor 1 possesses an α,β-diketoamide and exploits strong nucleophilicity of the mutant cysteine and irreversibly binds in the Switch II region of KRas. KRas G12R inhibitor 1 can be researched for K-Ras (G12R)-driven cancer such as pancreatic ductal adenocarcinoma (PDAC) .

HY-171776

OPB-3206	MMP	Cancer
OPB-3206 is a selective matrix metalloproteinase (MMP) inhibitor. OPB-3206 inhibits interstitial collagenase, gelatinase A (MMP-2), gelatinase B (MMP-9) and stromelysin with IC₅₀ values of 7×10 ^-7 M, 5×10 ^-6 M, 5×10 ^-7 M and 2×10 ^-6 M, respectively. OPB-3206 reversibly binds to the zinc-binding region of MMPs, preventing the activation of MMP-9 and reducing extracellular matrix degradation to inhibit tumor lung metastasis. OPB-3206 is promising for research of lung metastasis of osteosarcoma .

HY-110374

NVS-CECR2-1	Epigenetic Reader Domain Apoptosis	Cancer
NVS-CECR2-1, a non-BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS-CECR2-1 binds to CECR2 BRD with high affinity (IC₅₀=47 nM; K_D=80 nM). NVS-CECR2-1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2-independent mechanism . NVS-CECR2-1 is a chemical probe.

HY-W010041R

Scyllo-Inositol (Standard)	α-synuclein Amyloid-β	Neurological Disease
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-W010041

Scyllo-Inositol	α-synuclein Amyloid-β	Neurological Disease
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-W707693

Scyllo-Inositol-d6	Isotope-Labeled Compounds Amyloid-β α-synuclein	Neurological Disease
Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-W040129

Chromomycin A3 1 Publications Verification	DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis Caspase	Infection Neurological Disease Cancer
Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg ²⁺. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .

HY-159834

Progerinin SLC-D011	DNA/RNA Synthesis	Others
Progerinin (SLC-D011) is an orally active progerin-lamin A binding inhibitor. Progerinin selectively binds to the C-terminal region of progerin, disrupting its interaction with lamin A and promoting progerin degradation while sparing wild-type lamin A, B, and C. Progerinin ameliorates nuclear deformation, increases H3K9me3 levels, and reduces progerin expression in HGPS patient-derived fibroblasts. Progerinin extends lifespan in Lmna ^G609G/G609G mice and Lmna ^G609G/+ mice, improves body weight, hair morphology, cardiac function, and histological phenotypes. Progerinin can be used for the study of Hutchinson-Gilford progeria syndrome (HGPS) .

HY-164552

ZNU-IMB-Z15	Apoptosis Androgen Receptor	Cancer
ZNU-IMB-Z15 (Compound Z15) is an antagonist of the androgen receptor (AR) and also a selective degrader of AR and ARV7. ZNU-IMB-Z15 can directly bind to the ligand-binding domain (LBD) and activation function-1 region of AR, and promote AR degradation through the proteasome pathway. ZNU-IMB-Z15 effectively inhibits the transcriptional activity of AR, AR mutants, and AR splice variants (ARVs), downregulating the mRNA and protein levels of AR downstream target genes, thereby overcoming the resistance to second-generation antiandrogen drugs induced by AR LBD mutations, AR amplification, and ARVs in castration-resistant prostate cancer (CRPC). ZNU-IMB-Z15 can inhibit the proliferation of AR-positive CRPC cell lines and induce their apoptosis, demonstrating anticancer activity both in vivo and in vitro .

HY-W040129R

Chromomycin A3 (Standard)	Reference Standards Bacterial Fungal Apoptosis Antibiotic	Infection Neurological Disease Cancer
Chromomycin A3 (Standard) is the analytical standard of Chromomycin A3 (HY-W040129). This product is intended for research and analytical applications. Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg ²⁺. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .

Cat. No.	Product Name	Target	Research Area

HY-P1996

Tiplimotide NBI-5788	Peptides	Neurological Disease Inflammation/Immunology
Tiplimotide (NBI-5788) is an altered peptide ligand (APL) designed from an immunodominant region (83-99) of the neuroantigen myelin basic protein (MBP). Tiplimotide can selectively reduce the production of inflammatory cytokines by pathogenic T-cells. Tiplimotide can be used for the research of multiple sclerosis (MS) .

Cat. No.	Product Name	Target	Research Area

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-P99382A

Vopratelimab (Mouse IgG2a)	Inhibitory Antibodies	Cancer
Vopratelimab (Mouse IgG2a) is a monoclonal antibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy .

HY-P990109

Aducanumab (Mouse IGG2a)	Amyloid-β	Neurological Disease
Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC₅₀s of >1 μM and 0.2 nM for monomeric Aβ_1-40 and fibrillar Aβ_1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113294

3-Hydroxykynurenine 3-Hydroxy-DL-kynurenine	Structural Classification Monophenols Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite Apoptosis
3-Hydroxykynurenine, a metabolite of tryptophan, is a potential endogenous neurotoxin whose increased levels have been described in several neurodegenerative disorders. 3-Hydroxykynurenine induces neuronal apoptosis .

HY-W010041

Scyllo-Inositol	Structural Classification Natural Products Source classification Endogenous metabolite	α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-W040129

Chromomycin A3 1 Publications Verification	Microorganisms Source classification	DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis Caspase
Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg ²⁺. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .

HY-W010041R

Scyllo-Inositol (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-W040129R

Chromomycin A3 (Standard)	Microorganisms Source classification	Reference Standards Bacterial Fungal Apoptosis Antibiotic
Chromomycin A3 (Standard) is the analytical standard of Chromomycin A3 (HY-W040129). This product is intended for research and analytical applications. Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg ²⁺. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .

Cat. No.	Product Name	Chemical Structure

HY-W707693

Scyllo-Inositol-d6
Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

Scyllo-Inositol-d6

Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

region selectivity

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products